Abstract
To determine the time to disease recurrence with long-acting injectable fluocinolone acetonide implant (FAi) for noninfectious intermediate, posterior, and panuveitis. This was a retrospective study of patients with at least 12months of follow-up who had completed a 2-year prospective, investigational new drug study with 0.18-mg FAi. Time to uveitis recurrence or cystoid macular edema (CME) occurrence was recorded. Twelve eyes from 12 participants (mean age 43years, range 25-64years) were included. Patients were followed for a mean of 34.2months (range, 12.0-56.9months) after completion of the prospective trial. Five eyes (42%) did not have a documented uveitis recurrence or CME occurrence. Five eyes (42%) had a uveitis recurrence with the mean time to recurrence 36.1months (range, 22.8-61.1months) after FAi implantation. Two eyes (16%) had CME alone, the mean time to occurrence 36.9months (range 36.1-42.1months). On Kaplan-Meier analysis, the estimated probability of remaining recurrence-free 36months after FAi implantation was 0.67 (95% confidence interval, 0.34-0.86). Data of study participants after completing a clinical trial suggest that the injectable FAi for noninfectious uveitis can provide control for 3years on average. These long-term data support the use of FAi to control noninfectious uveitis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Graefe's Archive for Clinical and Experimental Ophthalmology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
